 NORCROSS, Ga., March 31, 2021 GLOBE NEWSWIRE -- Galectin Therapeutics Inc. NASDAQ: GALT, the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020. These results are included in the Companys Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at . 